Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04331639 · ClinicalTrials.gov registry record

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

A clinical trial of Ulcerative Colitis and Crohn Disease, sponsored by Boston Children's Hospital.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT04331639 is a study of Ulcerative Colitis and Crohn Disease that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 50 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04331639, a study of Ulcerative Colitis and Crohn Disease, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

Interventions

  • DIETARY_SUPPLEMENT vitamin D3

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-11-01
Est. Completion 2025-12-31

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT04331639

The ClinicalTrials.gov registry entry for NCT04331639 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which vitamin D3 is the first listed.

NCT04331639 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04331639 about?

NCT04331639 is a clinical study titled "High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy". The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

What is the current status of trial NCT04331639?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-11-01. Estimated completion is 2025-12-31.

What conditions does trial NCT04331639 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Vitamin D Deficiency, Inflammatory Bowel Disease.

What interventions are being tested in trial NCT04331639?

The interventions under investigation include: vitamin D3 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04331639?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04331639 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.